Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Sihuan Pharmaceutical Holdings Group stock price, quote, forecast and news

460.HK
BMG8162K1137
A1C72G

Price

0.49
Today +/-
+0
Today %
+0 %
P

Sihuan Pharmaceutical Holdings Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Sihuan Pharmaceutical Holdings Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sihuan Pharmaceutical Holdings Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sihuan Pharmaceutical Holdings Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Sihuan Pharmaceutical Holdings Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Sihuan Pharmaceutical Holdings Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Sihuan Pharmaceutical Holdings Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sihuan Pharmaceutical Holdings Group’s growth potential.

Sihuan Pharmaceutical Holdings Group Revenue, EBIT and net profit per share

DateSihuan Pharmaceutical Holdings Group RevenueSihuan Pharmaceutical Holdings Group EBITSihuan Pharmaceutical Holdings Group Net Income
2026e12.85 B undefined9.51 B undefined2.41 B undefined
2025e2.54 B undefined-574.7 M undefined103.12 M undefined
2024e2.17 B undefined-766.2 M undefined23.44 M undefined
20231.86 B undefined-140.54 M undefined-54.02 M undefined
20222.18 B undefined-536.03 M undefined-1.91 B undefined
20213.04 B undefined676.2 M undefined416.51 M undefined
20202.46 B undefined485.82 M undefined473.38 M undefined
20192.88 B undefined1.39 B undefined-2.75 B undefined
20182.92 B undefined1.72 B undefined1.62 B undefined
20172.75 B undefined1.47 B undefined1.45 B undefined
20163.19 B undefined1.94 B undefined1.71 B undefined
20153.17 B undefined2.07 B undefined2.06 B undefined
20143.08 B undefined1.98 B undefined1.67 B undefined
20132.59 B undefined1.5 B undefined1.28 B undefined
20123.04 B undefined1.02 B undefined904.4 M undefined
20112.24 B undefined997.9 M undefined824 M undefined
20101.04 B undefined615.8 M undefined522.1 M undefined
2009708.9 M undefined415.3 M undefined326.3 M undefined
2008510 M undefined300.5 M undefined237.1 M undefined
2007286.3 M undefined174.6 M undefined179.3 M undefined
2006161.8 M undefined108.9 M undefined90.5 M undefined
2005101.6 M undefined45.8 M undefined38.2 M undefined
200462 M undefined26 M undefined22.2 M undefined

Sihuan Pharmaceutical Holdings Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0.050.060.10.160.290.510.711.042.243.042.593.083.173.192.752.922.882.463.042.181.862.172.5412.85
-21.5762.9059.4177.6478.3238.8246.33116.4135.68-14.9919.262.690.57-13.816.27-1.34-14.3823.30-28.21-14.7216.7716.90406.22
52.9456.4554.4677.0278.6773.7373.0271.8176.4575.2556.2668.4570.3568.7072.3581.5679.5377.6879.9968.1869.62---
0.030.040.060.120.230.380.520.741.712.291.462.112.232.191.992.382.291.912.431.491.3000
0.020.030.050.110.170.30.420.6211.021.51.982.071.941.471.721.390.490.68-0.54-0.14-0.77-0.579.51
33.3341.9444.5567.0860.8458.8258.6259.3644.4733.6057.8964.1765.4960.7553.3759.0748.4419.6822.25-24.58-7.53-35.27-22.6173.97
0.020.020.040.090.180.240.330.520.820.91.281.672.061.711.451.62-2.750.470.42-1.91-0.050.020.12.41
-29.4172.73136.8498.8932.4037.5560.1257.859.7142.0430.1423.40-17.17-15.2211.81-270.04-117.18-12.05-560.10-97.18-142.59347.832,240.78
------------------------
------------------------
0.750.750.940.940.90.947.58.0110.3610.3510.3510.3610.3610.149.489.479.479.479.489.339.3000
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Sihuan Pharmaceutical Holdings Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Sihuan Pharmaceutical Holdings Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Sihuan Pharmaceutical Holdings Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Sihuan Pharmaceutical Holdings Group's financial health and stability.

Assets

Sihuan Pharmaceutical Holdings Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Sihuan Pharmaceutical Holdings Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Sihuan Pharmaceutical Holdings Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Sihuan Pharmaceutical Holdings Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20032004200520062007200820092010201120122013201420152016201720182019202020212022
0.020.020.040.090.180.290.380.641.041.171.62.072.842.151.732.01-2.470.770.49-2.12
334101426283694127134170246274282286348270301361
00000000000000000000
-4-97-42-3-66-57-284-379-130-165-443-791-329143-276-343-624-413-11
-000.010.02-0.010.010.03-0.01-0.05-0.120-0.04-0.73-0.08-0.24-0.233.88-0.190.291.82
0000000000850001002755
00212112653135215237340249646595441504509214203156
0.020.020.060.080.180.260.390.380.711.051.571.761.572.021.921.791.420.230.670.05
-3-13-17-49-86-44-68-142-358-714-1,080-493-517-279-428-282-589-580-725-593
-11-17-39-49-155-11516-363-2,862-2,764-491-1,558-3860-2,097822551-924-337-1,661
-0.01-0-0.020-0.07-0.070.08-0.22-2.5-2.050.59-1.070.130.28-1.671.11.14-0.340.39-1.07
00000000000000000000
0024-18-4-1200-11767-523-18340-387-91723290152
00000.2005.4-0.040000-1.24-0.250-0.010-0.20
0-0-0.01-00.19-0.07-0.125.22-0.550.11-1.05-0.44-0.26-1.89-1.4-0.13-0.170.180.75-0.24
0-1-3215000004-2-5916-49320131904860924
00000-60-120-173-502-662-522-243-279-607-1,144-240-198-1,444-196-1,315
000.010.020.220.070.285.24-2.7-1.610.03-0.240.920.12-1.582.481.8-0.511.08-1.85
11.46.539.626.295.8212.7316.9237.2354331.5493.11,267.361,051.481,738.581,489.121,510.77827.93-353.48-60.29-547.44
00000000000000000000

Sihuan Pharmaceutical Holdings Group stock margins

The Sihuan Pharmaceutical Holdings Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sihuan Pharmaceutical Holdings Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sihuan Pharmaceutical Holdings Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Sihuan Pharmaceutical Holdings Group's sales revenue. A higher gross margin percentage indicates that the Sihuan Pharmaceutical Holdings Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Sihuan Pharmaceutical Holdings Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Sihuan Pharmaceutical Holdings Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sihuan Pharmaceutical Holdings Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sihuan Pharmaceutical Holdings Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sihuan Pharmaceutical Holdings Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Sihuan Pharmaceutical Holdings Group Margin History

Sihuan Pharmaceutical Holdings Group Gross marginSihuan Pharmaceutical Holdings Group Profit marginSihuan Pharmaceutical Holdings Group EBIT marginSihuan Pharmaceutical Holdings Group Profit margin
2026e69.64 %73.97 %18.76 %
2025e69.64 %-22.63 %4.06 %
2024e69.64 %-35.28 %1.08 %
202369.64 %-7.55 %-2.9 %
202268.2 %-24.58 %-87.79 %
202179.99 %22.26 %13.71 %
202077.69 %19.71 %19.21 %
201979.54 %48.45 %-95.66 %
201881.55 %59.08 %55.53 %
201772.36 %53.35 %52.77 %
201668.71 %60.75 %53.62 %
201570.35 %65.51 %65.12 %
201468.46 %64.17 %54.19 %
201356.28 %57.88 %49.68 %
201275.25 %33.62 %29.73 %
201176.47 %44.51 %36.75 %
201071.82 %59.39 %50.35 %
200972.93 %58.58 %46.03 %
200873.82 %58.92 %46.49 %
200778.87 %60.98 %62.63 %
200677.19 %67.31 %55.93 %
200554.33 %45.08 %37.6 %
200457.1 %41.94 %35.81 %

Sihuan Pharmaceutical Holdings Group Stock Sales Revenue, EBIT, Earnings per Share

The Sihuan Pharmaceutical Holdings Group earnings per share therefore indicates how much revenue Sihuan Pharmaceutical Holdings Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sihuan Pharmaceutical Holdings Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sihuan Pharmaceutical Holdings Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sihuan Pharmaceutical Holdings Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sihuan Pharmaceutical Holdings Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sihuan Pharmaceutical Holdings Group Revenue, EBIT and net profit per share

DateSihuan Pharmaceutical Holdings Group Sales per ShareSihuan Pharmaceutical Holdings Group EBIT per shareSihuan Pharmaceutical Holdings Group Earnings per Share
2026e1.38 undefined0 undefined0.26 undefined
2025e0.27 undefined0 undefined0.01 undefined
2024e0.23 undefined0 undefined0 undefined
20230.2 undefined-0.02 undefined-0.01 undefined
20220.23 undefined-0.06 undefined-0.21 undefined
20210.32 undefined0.07 undefined0.04 undefined
20200.26 undefined0.05 undefined0.05 undefined
20190.3 undefined0.15 undefined-0.29 undefined
20180.31 undefined0.18 undefined0.17 undefined
20170.29 undefined0.15 undefined0.15 undefined
20160.31 undefined0.19 undefined0.17 undefined
20150.31 undefined0.2 undefined0.2 undefined
20140.3 undefined0.19 undefined0.16 undefined
20130.25 undefined0.14 undefined0.12 undefined
20120.29 undefined0.1 undefined0.09 undefined
20110.22 undefined0.1 undefined0.08 undefined
20100.13 undefined0.08 undefined0.07 undefined
20090.09 undefined0.06 undefined0.04 undefined
20080.54 undefined0.32 undefined0.25 undefined
20070.32 undefined0.19 undefined0.2 undefined
20060.17 undefined0.12 undefined0.1 undefined
20050.11 undefined0.05 undefined0.04 undefined
20040.08 undefined0.03 undefined0.03 undefined

Sihuan Pharmaceutical Holdings Group business model

Sihuan Pharmaceutical Holdings Group Ltd is a leading company in the Chinese pharmaceutical industry that focuses on research, development, production, and marketing of drugs, especially for the treatment of cardiovascular diseases and central nervous system diseases. The company was founded in 2001 and has become one of the largest and most successful companies in the Chinese pharmaceutical industry. It is listed on the stock exchange and has its headquarters in Beijing, China. Sihuan Pharmaceutical's business model is based on a combined strategy of researching and developing new drugs tailored to the Chinese market, as well as licensing and distributing existing drugs from both domestic and international sources. The company is divided into various business divisions to maximize its core competencies and maintain growth. The cardiovascular division is one of the most important divisions, producing and distributing cardiovascular drugs used to treat conditions such as hypertension, heart failure, arrhythmias, and other cardiovascular diseases. The central nervous system division is another important division, producing and distributing drugs to treat neurological disorders such as depression, schizophrenia, and epilepsy. In addition, the company also has products in the areas of antibiotics, antivirals, and gastroenterology. Sihuan Pharmaceutical's research and development department focuses on the discovery and development of new active substances, as well as improving existing drugs. The company collaborates with leading universities and research institutions in China and globally to develop innovative approaches in pharmacy. Sihuan Pharmaceutical has also established a strong presence in the Chinese market, building an extensive distribution network throughout China and working closely with other key players in the industry to strengthen its market position. In summary, Sihuan Pharmaceutical Holdings Group Ltd is a significant player in the Chinese pharmaceutical industry, specializing in the research, development, production, and marketing of drugs for the treatment of cardiovascular diseases and central nervous system diseases. The company is divided into multiple business divisions and has a strong presence in the Chinese market. With its strong research and development department, Sihuan Pharmaceutical is committed to improving the health and well-being of millions of people worldwide. Sihuan Pharmaceutical Holdings Group is one of the most popular companies on Eulerpool.com.

Sihuan Pharmaceutical Holdings Group SWOT Analysis

Strengths

Sihuan Pharmaceutical Holdings Group Ltd has several notable strengths that contribute to its competitive advantage in the pharmaceutical industry. Firstly, the company has a strong research and development (R&D) division, which enables it to innovate and develop new drugs. This helps Sihuan Pharmaceutical stay ahead of its competitors and offer unique solutions to patients. Additionally, the company has a wide range of product offerings, encompassing various therapeutic areas, giving it a diversified revenue stream.

Weaknesses

Despite its strengths, Sihuan Pharmaceutical also faces certain weaknesses that hinder its growth potential. One notable weakness is its limited geographical reach. Although the company is well-established in the domestic market, its global presence is relatively limited. Expanding into new markets and establishing a stronger international presence could help mitigate this weakness and tap into untapped potential.

Opportunities

Sihuan Pharmaceutical operates in an industry with several opportunities for growth and expansion. One major opportunity lies in the aging population worldwide. The increasing prevalence of chronic diseases among the elderly presents a significant market for pharmaceutical companies, including Sihuan. By focusing on developing drugs to address these diseases, the company can tap into this growing market and enhance its revenue stream. Additionally, advancements in technology and digital healthcare solutions offer an opportunity for Sihuan to explore new ways of delivering healthcare services and improving patient outcomes.

Threats

Alongside opportunities, Sihuan Pharmaceutical also faces various threats that could impact its operations. One prominent threat is the intense competition within the pharmaceutical industry. The presence of large multinational companies and local players poses a challenge to Sihuan's market share and profitability. Additionally, stringent regulations and the lengthy drug approval process can hinder the company's ability to bring new drugs to market quickly. Economic fluctuations, such as currency exchange rate fluctuations, can also impact Sihuan's financial performance and sales in international markets.

Sihuan Pharmaceutical Holdings Group historical P/E ratio, EBIT, and P/S ratio.

Sihuan Pharmaceutical Holdings Group shares outstanding

The number of shares was Sihuan Pharmaceutical Holdings Group in 2023 — This indicates how many shares 9.297 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sihuan Pharmaceutical Holdings Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sihuan Pharmaceutical Holdings Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sihuan Pharmaceutical Holdings Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sihuan Pharmaceutical Holdings Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sihuan Pharmaceutical Holdings Group Stock splits

In Sihuan Pharmaceutical Holdings Group's history, there have been no stock splits.

Sihuan Pharmaceutical Holdings Group dividend history and estimates

In 2023, Sihuan Pharmaceutical Holdings Group paid a dividend amounting to 0.07 CNY. Dividend means that Sihuan Pharmaceutical Holdings Group distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Sihuan Pharmaceutical Holdings Group provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Sihuan Pharmaceutical Holdings Group’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Sihuan Pharmaceutical Holdings Group's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Sihuan Pharmaceutical Holdings Group Dividend History

DateSihuan Pharmaceutical Holdings Group Dividend
2026e0.08 undefined
2025e0.07 undefined
2024e0.09 undefined
20230.07 undefined
20220.12 undefined
20210.02 undefined
20200.15 undefined
20190.02 undefined
20180.02 undefined
20170.08 undefined
20160.07 undefined
20150.03 undefined
20140.02 undefined
20130.05 undefined
20120.03 undefined
20110.01 undefined

Sihuan Pharmaceutical Holdings Group dividend payout ratio

In 2023, Sihuan Pharmaceutical Holdings Group had a payout ratio of 108.81%. The payout ratio indicates the percentage of the company's profits that Sihuan Pharmaceutical Holdings Group distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Sihuan Pharmaceutical Holdings Group represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Sihuan Pharmaceutical Holdings Group could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Sihuan Pharmaceutical Holdings Group's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Sihuan Pharmaceutical Holdings Group Payout Ratio History

DateSihuan Pharmaceutical Holdings Group Payout ratio
2026e114.97 %
2025e95.12 %
2024e140.99 %
2023108.81 %
2022-56.42 %
202135.56 %
2020278.58 %
2019-6.81 %
201812.28 %
201753.66 %
201640.96 %
201516.58 %
201414.57 %
201342.08 %
201231.11 %
201111.88 %
2010108.81 %
2009108.81 %
2008108.81 %
2007108.81 %
2006108.81 %
2005108.81 %
2004108.81 %
Unfortunately, there are currently no price targets and forecasts available for Sihuan Pharmaceutical Holdings Group.

Sihuan Pharmaceutical Holdings Group latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20170.11 0.06  (-42.39 %)2017 Q4
6/30/20170.07 0.09  (25.88 %)2017 Q2
6/30/20160.09 0.07  (-22.99 %)2016 Q2
6/30/20150.09 0.14  (54.02 %)2015 Q2
12/31/20140.09 0.08  (-8.69 %)2014 Q4
6/30/20140.08 0.08  (-0.99 %)2014 Q2
6/30/20130.06 0.06  (7.59 %)2013 Q2
12/31/20120.05 0.04  (-17.31 %)2012 Q4
6/30/20120.04 0.04  (10.15 %)2012 Q2
12/31/20110.05 0.04  (-8.51 %)2011 Q4
1
2

Eulerpool ESG Scorecard© for the Sihuan Pharmaceutical Holdings Group stock

Eulerpool World ESG Rating (EESG©)

76/ 100

🌱 Environment

79

👫 Social

77

🏛️ Governance

71

Environment

Scope 1 - Direct Emissions
52,191.66
Scope 2 - Indirect emissions from purchased energy
71,100.59
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
123,292.25
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees57.26
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Sihuan Pharmaceutical Holdings Group list of shareholders

%
Name
Stocks
Change
Date
5.36 % Network Victory Ltd497,448,000012/31/2022
4.06 % Victory Faith International Ltd.377,267,528012/31/2022
31.06 % Proper Process International Ltd.2,882,469,225012/31/2022
2.75 % Mingyao Capital Ltd.255,582,886012/31/2022
11.86 % Successmax Global Holdings Ltd.1,100,884,399012/31/2022
1.33 % The Vanguard Group, Inc.123,136,630-1,035,0003/31/2024
0.73 % Bosera Asset Management Co., Ltd.67,324,00016,425,00012/31/2023
0.66 % BlackRock Institutional Trust Company, N.A.61,396,00078,0003/31/2024
0.60 % GF Fund Management Co., Ltd.56,020,00034,504,00012/31/2023
0.60 % Dimensional Fund Advisors, L.P.55,777,00002/29/2024
1
2
3
4
5
...
7

Sihuan Pharmaceutical Holdings Group Executives and Management Board

Dr. Fengsheng Che61
Sihuan Pharmaceutical Holdings Group Executive Chairman of the Board (since 2006)
Compensation 7 M
Dr. Weicheng Guo59
Sihuan Pharmaceutical Holdings Group Executive Deputy Chairman of the Board, Chief Executive Officer (since 2006)
Compensation 3.15 M
Ms. Yanling Chen45
Sihuan Pharmaceutical Holdings Group Executive Director, Joint Company Secretary (since 2018)
Compensation 1.8 M
Ms. Guili Miao49
Sihuan Pharmaceutical Holdings Group Deputy Chief Executive Officer, Chief Financial Officer, Executive Director (since 2022)
Compensation 1.59 M
Dr. Jionglong Zhang61
Sihuan Pharmaceutical Holdings Group Executive Director (since 2006)
Compensation 742,000
1
2

Sihuan Pharmaceutical Holdings Group Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Laboratory Corp Stock
Laboratory Corp
SupplierCustomer0,690,780,46-0,03-0,020,67
Strides Pharma Science Stock
Strides Pharma Science
SupplierCustomer0,590,820,260,010,880,41
Abliva Stock
Abliva
SupplierCustomer0,540,810,350,020,82-0,37
Ardelyx Stock
Ardelyx
SupplierCustomer-0,140,33-0,13-0,150,840,03
1

Most common questions regarding Sihuan Pharmaceutical Holdings Group

What values and corporate philosophy does Sihuan Pharmaceutical Holdings Group represent?

Sihuan Pharmaceutical Holdings Group Ltd represents several core values and a strong corporate philosophy. As a leading pharmaceutical company in China, Sihuan Pharma is committed to delivering high-quality healthcare solutions to improve patients' lives. Their corporate philosophy revolves around innovation, integrity, and dedication. By focusing on research and development, Sihuan Pharma strives to introduce breakthrough drugs and contribute to medical advancements globally. With a customer-centric approach, the company ensures access to affordable medications while maintaining strict quality control standards. Sihuan Pharmaceutical Holdings Group Ltd's dedication to excellence and commitment to improving healthcare exemplify their core values and corporate philosophy.

In which countries and regions is Sihuan Pharmaceutical Holdings Group primarily present?

Sihuan Pharmaceutical Holdings Group Ltd primarily operates in China.

What significant milestones has the company Sihuan Pharmaceutical Holdings Group achieved?

Sihuan Pharmaceutical Holdings Group Ltd, a leading pharmaceutical company, has achieved several significant milestones. The company successfully listed its shares on the Hong Kong Stock Exchange, making it one of the first Chinese pharmaceutical companies to do so. Sihuan Pharmaceutical has established a strong presence in the global market, expanding its network of subsidiaries and joint ventures across multiple countries. The company has made substantial investments in research and development, resulting in the development of innovative drugs and therapies. Sihuan Pharmaceutical has also secured various partnerships and collaborations with renowned international pharmaceutical companies, further enhancing its growth and market position. These achievements highlight the company's commitment to advancing healthcare and delivering innovative pharmaceutical solutions.

What is the history and background of the company Sihuan Pharmaceutical Holdings Group?

Sihuan Pharmaceutical Holdings Group Ltd is a leading pharmaceutical company that specializes in research, development, manufacturing, and marketing of therapeutic drugs. Founded in 2001 and headquartered in Beijing, China, the company has a rich history of providing innovative and high-quality healthcare solutions. With a focus on cardiovascular and cerebrovascular diseases, oncology, and diabetes treatments, Sihuan Pharmaceutical has become a trusted brand both within China and internationally. Through strategic partnerships, advanced technology, and a commitment to excellence, the company continues to make significant contributions to the medical field, improving patient outcomes, and driving growth in the pharmaceutical industry.

Who are the main competitors of Sihuan Pharmaceutical Holdings Group in the market?

The main competitors of Sihuan Pharmaceutical Holdings Group Ltd in the market are other prominent pharmaceutical companies operating in the same sector. Some notable competitors include Jiangsu Hengrui Medicine Co., Ltd., Sino Biopharmaceutical Limited, and Shanghai Pharmaceuticals Holding Co., Ltd. These companies compete with Sihuan Pharmaceutical in terms of research and development, product offerings, market presence, and overall industry reputation. Sihuan Pharmaceutical Holdings Group Ltd faces a competitive landscape as it strives to maintain its position and market share in the pharmaceutical industry.

In which industries is Sihuan Pharmaceutical Holdings Group primarily active?

Sihuan Pharmaceutical Holdings Group Ltd is primarily active in the pharmaceutical industry.

What is the business model of Sihuan Pharmaceutical Holdings Group?

The business model of Sihuan Pharmaceutical Holdings Group Ltd revolves around researching, developing, manufacturing, and commercializing pharmaceutical products. The company focuses on the research and development of innovative drugs, as well as the acquisition and licensing of technologies and intellectual properties. Sihuan Pharmaceutical Group primarily operates in the Chinese pharmaceutical market, offering a diverse range of therapeutic products targeting various diseases and medical conditions. Through its rigorous clinical trials and efficient production processes, the company aims to deliver high-quality medicines to improve patients' lives. Sihuan Pharmaceutical Group's business model highlights its commitment to innovation, quality, and meeting the healthcare needs of the Chinese market.

What is the P/E ratio of Sihuan Pharmaceutical Holdings Group 2024?

The Sihuan Pharmaceutical Holdings Group P/E ratio is 194.48.

What is the P/S ratio of Sihuan Pharmaceutical Holdings Group 2024?

The Sihuan Pharmaceutical Holdings Group P/S ratio is 2.1.

What is the AlleAktien quality score of Sihuan Pharmaceutical Holdings Group?

The AlleAktien quality score for Sihuan Pharmaceutical Holdings Group is 1/10.

What is the revenue of Sihuan Pharmaceutical Holdings Group 2024?

The expected Sihuan Pharmaceutical Holdings Group revenue is 2.17 B CNY.

How high is the profit of Sihuan Pharmaceutical Holdings Group 2024?

The expected Sihuan Pharmaceutical Holdings Group profit is 23.44 M CNY.

What is the business model of Sihuan Pharmaceutical Holdings Group

Sihuan Pharmaceutical Holdings Group Ltd is a leading Chinese pharmaceutical company based in Beijing. The company's business model includes three main areas: research and development, manufacturing, and marketing.

What is the Sihuan Pharmaceutical Holdings Group dividend?

Sihuan Pharmaceutical Holdings Group pays a dividend of 0.12 CNY distributed over payouts per year.

How often does Sihuan Pharmaceutical Holdings Group pay dividends?

The dividend cannot currently be calculated for Sihuan Pharmaceutical Holdings Group or the company does not pay out a dividend.

What is the Sihuan Pharmaceutical Holdings Group ISIN?

The ISIN of Sihuan Pharmaceutical Holdings Group is BMG8162K1137.

What is the Sihuan Pharmaceutical Holdings Group WKN?

The WKN of Sihuan Pharmaceutical Holdings Group is A1C72G.

What is the Sihuan Pharmaceutical Holdings Group ticker?

The ticker of Sihuan Pharmaceutical Holdings Group is 460.HK.

How much dividend does Sihuan Pharmaceutical Holdings Group pay?

Over the past 12 months, Sihuan Pharmaceutical Holdings Group paid a dividend of 0.07 CNY . This corresponds to a dividend yield of about 15.09 %. For the coming 12 months, Sihuan Pharmaceutical Holdings Group is expected to pay a dividend of 0.07 CNY.

What is the dividend yield of Sihuan Pharmaceutical Holdings Group?

The current dividend yield of Sihuan Pharmaceutical Holdings Group is 15.09 %.

When does Sihuan Pharmaceutical Holdings Group pay dividends?

Sihuan Pharmaceutical Holdings Group pays a quarterly dividend. This is distributed in the months of August, June, October, July.

How secure is the dividend of Sihuan Pharmaceutical Holdings Group?

Sihuan Pharmaceutical Holdings Group paid dividends every year for the past 16 years.

What is the dividend of Sihuan Pharmaceutical Holdings Group?

For the upcoming 12 months, dividends amounting to 0.07 CNY are expected. This corresponds to a dividend yield of 14.8 %.

In which sector is Sihuan Pharmaceutical Holdings Group located?

Sihuan Pharmaceutical Holdings Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sihuan Pharmaceutical Holdings Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sihuan Pharmaceutical Holdings Group from 6/23/2023 amounting to 0.037 CNY, you needed to have the stock in your portfolio before the ex-date on 6/6/2023.

When did Sihuan Pharmaceutical Holdings Group pay the last dividend?

The last dividend was paid out on 6/23/2023.

What was the dividend of Sihuan Pharmaceutical Holdings Group in the year 2023?

In the year 2023, Sihuan Pharmaceutical Holdings Group distributed 0.118 CNY as dividends.

In which currency does Sihuan Pharmaceutical Holdings Group pay out the dividend?

The dividends of Sihuan Pharmaceutical Holdings Group are distributed in CNY.

All fundamentals about Sihuan Pharmaceutical Holdings Group

Our stock analysis for Sihuan Pharmaceutical Holdings Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sihuan Pharmaceutical Holdings Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.